Welcome to the Department of Energy-sponsored Beryllium BioBank (BBB) Web Page. This site is designed to assist individuals in understanding the overall organizational structure, mechanism of study, and research goals of the BBB. The Beryllium BioBank consists of a Data Coordinating Center, housed at the University of Colorado Denver, Colorado School of Public Health and a Core Specimen Laboratory, housed at National Jewish Health in Denver, Colorado.
The Department of Energy, assisted by a group of clinicians and scientists from National Jewish Health, Hospital of the University of Pennsylvania, East Tennessee Pulmonary Associates, University of California-San Francisco, and University of California- Los Angeles collected clinical data and specimens for the Beryllium BioBank. The purpose of the repository is to facilitate research by collecting de-identified biological specimens and clinical information from a large number of workers exposed to beryllium. The BioBank does not directly conduct research.
The BioBank is a resource for future researchers to:
• Identify exposure and genetic risk factors that cause beryllium sensitization and disease
• Improve the detection of beryllium sensitization and CBD
• Define new therapeutics to be tested in the treatment of CBD
• Understand the immune and inflammatory mechanisms that cause beryllium sensitization and CBD
• Develop new biological markers of exposure, biological effect, and disease
• Define clinical and physiologic aspects of beryllium sensitization and CBD
This effort is funded by the U.S. Department of Energy.